Physician profile
Eva Blanco
NPI 1285018838
$1,536.16
in general payments reported to CMS, 2019-2025
19 companies · $423 in 2025
The $423 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $222 · 2022: $330 · 2023: $244 · 2024: $318 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $306.19 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $254.80 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $155.02 | 2021-2025 | Farxiga |
| Novo Nordisk INC | $121.58 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Astellas Pharma US INC | $113.51 | 2021-2024 | Veozah |
| Amgen INC. | $109.71 | 2021-2024 | Prolia, Evenity, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.31 | 2021-2025 | Jardiance |
| Pfizer INC. | $67.81 | 2023-2024 | |
| Dexcom, INC. | $54.74 | 2024-2025 | Dexcom G6 Transmitter |
| Averitas Pharma INC. | $47.24 | 2024 | Qutenza |
| Bayer Healthcare Pharmaceuticals INC. | $35.26 | 2024 | |
| Smith+Nephew, INC. | $29.60 | 2025 | Grafix |
| Sanofi-Aventis U.S. LLC | $28.56 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.26 | 2022-2023 | Xifaxan |
| Exact Sciences Corporation | $23.41 | 2024 | Cologuard Collection Kit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $19.95 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $19.87 | 2024 | Zoryve |
| Merck Sharp & Dohme LLC | $15.96 | 2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $13.38 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Blanco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.